Viridian Therapeutics, Inc. VRDN Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

PVL

Palvella TherapeuticsPVLA

$209K—

RegenxbioRGNX

$7.36M-8.6%

Zevra Therapeutics, Inc.ZVRA

$626K+19.2%

Shattuck Labs, Inc.STTK

$874K-8.6%

Krystal Biotech, Inc.KRYS

$1.8M+32.2%

BioCryst PharmaceuticalsBCRX

$1.91M+388%

FAQ

What is Viridian Therapeutics, Inc.'s operating lease liabilities (current)?

Viridian Therapeutics, Inc. (VRDN) reported operating lease liabilities (current) of $722K in Q2 2026.

How has Viridian Therapeutics, Inc.'s operating lease liabilities (current) changed year-over-year?

Viridian Therapeutics, Inc.'s operating lease liabilities (current) increased by 30.6% year-over-year, from $553K to $722K.

What is the long-term trend for Viridian Therapeutics, Inc.'s operating lease liabilities (current)?

Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s operating lease liabilities (current) has grown at a 49.7% compound annual growth rate (CAGR), from $100K to $753K.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.